TB-500 + Epitalon Stack: Safety, Monitoring, and Protocol

What TB-500 and Epitalon Actually Are

These two peptides come from entirely different biological pathways, which is exactly why some practitioners combine them.

TB-500: The Thymosin Beta-4 Fragment

TB-500 refers to the tetradecapeptide Ac-SDKP, derived from the C-terminus of thymosin beta-4 (Tβ4). The full-length Tβ4 protein (43 amino acids) regulates actin polymerization, modulates inflammatory cytokines, and promotes angiogenesis. Research published in Annals of the New York Academy of Sciences confirmed that Tβ4 accelerates corneal wound healing and reduces cardiac inflammation in rodent infarct models 1.

Ac-SDKP, the fragment sold as "TB-500," circulates endogenously at picomolar concentrations. A 2004 study in Circulation found that Ac-SDKP inhibits collagen synthesis in cardiac fibroblasts and reduces TGF-β1-driven fibrosis in rats given ACE-inhibitor therapy 2. That anti-fibrotic effect is one reason athletes and biohackers use it for soft-tissue injuries.

The FDA removed TB-500 from the 503A bulk drug substances list in 2023, meaning licensed compounding pharmacies can no longer prepare it for individual patients under standard pathways 3.

Epitalon: The Pineal Tetrapeptide

Epitalon (Ala-Glu-Asp-Gly) is a synthetic version of epithalamin, isolated from bovine pineal extracts by Vladimir Khavinson's group at the St. Petersburg Institute of Bioregulation and Gerontology. Its proposed mechanism centers on telomerase activation. A peer-reviewed study in Bulletin of Experimental Biology and Medicine showed Epitalon increased telomerase activity and telomere length in human somatic cells in vitro 4.

Khavinson's group also published a 15-year observational study of 266 elderly patients treated with epithalamin (the natural extract, not the synthetic tetrapeptide) showing mortality reduction of approximately 28% compared to untreated controls 5. The methodology was not double-blinded, and the extract differs chemically from synthetic Epitalon, so this result cannot be directly applied to current compounded preparations.

Why Practitioners Stack These Two Peptides

The rationale is mechanistic, not trial-proven.

TB-500 targets the extracellular matrix, vascular remodeling, and acute inflammation. Epitalon targets cellular aging at the telomere level and may also modulate melatonin secretion and cortisol rhythms. Because the two pathways do not obviously overlap, some practitioners view them as complementary rather than redundant.

The Proposed Combination Argument

A 2007 paper in Peptides described thymosin peptides as broad immunomodulators affecting T-cell differentiation and cytokine balance 6. Proponents argue that TB-500's immune modulation pairs with Epitalon's purported neuroendocrine normalization to produce a broader anti-aging or recovery effect. That argument is mechanistically plausible. It is not yet experimentally confirmed in any co-administration study.

What the Evidence Cannot Tell Us

No published pharmacokinetic study has measured interaction between Ac-SDKP and Ala-Glu-Asp-Gly. Neither peptide is metabolized by CYP450 enzymes to a clinically meaningful degree, so classical drug-drug interactions are unlikely. Both are degraded by serum peptidases. Simultaneous injection could theoretically compete for peptidase clearance, but no data quantify this effect.

Safety Profile of TB-500 Alone

Understanding individual safety profiles is the foundation for evaluating the stack.

Known Adverse Effects

Reported adverse effects for TB-500 in practitioner case series include injection-site erythema, transient fatigue in the first week, and mild headache. No large prospective human safety study exists. A 2010 review in Cardiovascular Research noted that Tβ4 promotes endothelial cell migration and neovascularization, raising a theoretical concern about accelerating growth of occult tumors dependent on angiogenesis 7.

The Oncology Signal

This angiogenic concern is not hypothetical in the literature. A study in Journal of Molecular and Cellular Cardiology documented that Tβ4 upregulates vascular endothelial growth factor (VEGF) expression in cardiomyocytes 8. VEGF-driven angiogenesis is a recognized survival mechanism for solid tumors. Practitioners using TB-500 should rule out occult malignancy before and during a cycle. A normal PSA (men), mammography or breast exam (women), and a complete blood count with differential are reasonable minimums.

Contraindications

TB-500 is contraindicated in patients with any active malignancy, a personal history of hormone-sensitive cancer, or uncontrolled autoimmune disease. These are not absolute in every practitioner's framework, but the angiogenic mechanism supports treating them as firm lines until more human data exist.

Safety Profile of Epitalon Alone

Reported Adverse Effects

Epitalon has a notably sparse adverse-effect record in the published literature. Khavinson's group reported no serious adverse events across multiple small clinical series involving elderly patients receiving subcutaneous or intranasal epithalamin 5. Minor injection-site reactions are the most commonly described issue.

Melatonin and Cortisol Effects

A 1999 study in Neuroendocrinology Letters found that epithalamin restored nocturnal melatonin peaks in elderly women whose circadian secretion had declined with age 9. Practitioners using Epitalon report improved sleep quality as a common early effect. Cortisol modulation has been proposed but is not well-characterized in human studies. Patients on glucocorticoid therapy or with adrenal disease should use Epitalon with caution.

Long-Term Telomerase Concerns

Telomerase activation is the proposed longevity mechanism. Telomerase is also reactivated in approximately 85% of human cancers 10. Whether exogenous Epitalon at typical doses meaningfully raises cancer risk is unknown. The in-vitro telomerase data 4 used human fibroblasts, not transformed cancer cells, and no human carcinogenesis study has been conducted. The concern is theoretical but warrants pre-cycle cancer screening, particularly in patients over age 50.

The TB-500 + Epitalon Stack Protocol

No consensus protocol exists. The following represents a synthesis of practitioner-reported approaches and is not a clinical recommendation.

Loading Phase (Weeks 1 to 6, TB-500)

Practitioners commonly load TB-500 at 2.0 to 5.0 mg subcutaneous injection 2 to 3 times per week for 4 to 6 weeks. Animal studies use weight-based dosing; the 2003 rat infarct study used 150 mcg/kg 11, which would translate to approximately 10 to 12 mg per injection in a 70 kg human. Most practitioners use doses far below this extrapolation, citing the lack of human safety data at higher doses.

Epitalon Cycle (Concurrent or Sequential)

Epitalon is typically administered at 5 to 10 mg subcutaneous daily for 10 to 20 consecutive days. Some practitioners run this concurrently with the TB-500 loading phase. Others delay Epitalon until week 3 to assess TB-500 tolerability first. Sequential dosing has no published advantage over concurrent use, but the staged approach does simplify attribution of any adverse reaction to a single agent.

Maintenance and Cycle Frequency

After the TB-500 loading phase, some practitioners drop to a maintenance dose of 2.0 to 2.5 mg once per week for 4 to 8 additional weeks. Epitalon is sometimes repeated every 3 to 6 months. No data define the optimal cycle frequency for either peptide in humans. Practitioners generally advise against continuous, uninterrupted use of either agent given the absence of long-term safety data beyond Khavinson's observational series.

Injection Technique and Storage

Both peptides are supplied as lyophilized powder requiring reconstitution with bacteriostatic water. Subcutaneous injection into abdominal fat or the outer thigh is standard. Reconstituted solution should be stored at 2 to 8°C and used within 28 days. A 2022 FDA guidance document on compounded drug stability reminds practitioners that peptide potency degrades rapidly at room temperature and is highly sensitive to light exposure 3.

Monitoring Protocol: What to Check and When

This is the section most online sources skip entirely.

Baseline Labs Before Starting the Stack

| Test | Rationale | |---|---| | CBC with differential | Rule out hematologic malignancy; baseline for immune monitoring | | Comprehensive metabolic panel (CMP) | Hepatic and renal clearance baseline | | High-sensitivity CRP (hsCRP) | Inflammatory baseline before TB-500 anti-inflammatory effects begin | | PSA (men over 40) | TB-500 angiogenic concern in prostate tissue | | Estradiol + mammography (women over 40) | Epitalon's neuroendocrine effects on estrogen-sensitive tissue | | Fasting glucose and HbA1c | Epitalon has been reported to influence insulin secretion in animal models 12 | | IGF-1 | Some peptide stacks are paired with GH secretagogues; document baseline |

On-Cycle Monitoring

Repeat hsCRP at week 4. An unexpected rise (above 3.0 mg/L without infection) should prompt a pause and clinical review. Injection sites should be examined at each administration for signs of abscess, induration greater than 2 cm, or warmth spreading beyond 1 cm from the injection point. These findings warrant cessation and wound evaluation.

As the American College of Endocrinology has noted in its compounding guidance, "the absence of FDA oversight means practitioners must substitute clinical surveillance for regulatory safety assurance" 13. That principle applies directly here.

Post-Cycle Labs

Repeat CBC and CMP at cycle end (week 6 for the loading phase). Any new cytopenias, transaminase elevations above 2× the upper limit of normal, or creatinine rise of 0.3 mg/dL or more from baseline should be investigated before considering a repeat cycle.

Evidence Gaps and What We Do Not Know

Transparency matters more here than in most clinical topics.

The literature on Epitalon consists primarily of Khavinson's own publications, concentrated in Russian-language journals, with limited independent replication. A 2014 review in Current Aging Science acknowledged Khavinson's tetrapeptide bioregulator work while calling for "independent, double-blind, placebo-controlled trials in Western research centers to validate the telomere-length findings" 14.

TB-500 has more diverse research representation, but nearly all mechanistic work is rodent-based. The first published human data on thymosin beta-4 in cardiac repair came from a Phase II trial (REMEDY, NCT01311518) that found no significant benefit over placebo in post-myocardial-infarction patients 15. That trial used the full-length Tβ4 protein intravenously, not the Ac-SDKP fragment subcutaneously, so translation to TB-500 usage is indirect. The null result does not disprove benefit for the fragment at soft-tissue injury doses, but it illustrates the gap between animal promise and human outcome.

No interaction study, no pharmacokinetic co-administration data, and no comparative effectiveness trial exists for the TB-500 plus Epitalon combination. Practitioners and patients must weigh that reality explicitly.

Regulatory Status and Sourcing Risks

TB-500 cannot be legally dispensed by 503A compounding pharmacies in the United States as of 2023. Epitalon has never received FDA approval and is not on any approved compounding list. Both peptides are sold by research chemical vendors, whose products are not subject to cGMP standards, identity testing, or sterility assurance 3.

A 2021 study in JAMA Internal Medicine tested 10 commercially available research peptides and found that 3 contained less than 80% of labeled peptide content, and 1 was contaminated with bacterial endotoxin 16. Injecting endotoxin-contaminated peptide subcutaneously risks septic abscess or systemic inflammatory response. This sourcing risk compounds the pharmacological risks described above.

Practitioners operating within legal frameworks should confirm that any peptide used is sourced from a 503B outsourcing facility, which operates under FDA inspection, or should discuss investigational new drug pathways with legal counsel.

Stopping Rules

Stop both peptides immediately and seek clinical evaluation if any of the following occur:

• Fever above 38.5°C within 48 hours of any injection
• Injection site induration larger than 3 cm or spreading erythema
• New lymphadenopathy detected during the cycle
• Any unexplained weight loss of more than 2 kg over two weeks
• Jaundice, dark urine, or right upper-quadrant pain (hepatotoxicity screen)
• New or worsening dyspnea (consider cardiac or pulmonary pathology given TB-500 vascular effects)

These stopping rules reflect standard peptide-therapy clinical practice as outlined in integrative medicine safety frameworks and align with the general principles of the FDA MedWatch adverse event reporting program 17.